Here here Awoonga.We're sitting at a 30% rise which is nothing to be sneezed at.Management have ticked yet another box in their plan that they have kept restating for quite some time now.Roll on 2014.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
